松龄血脉康联合瑞舒伐他汀治疗老年睡眠呼吸暂停综合征动脉硬化

Effect of Songling Xuemaikang combined with rosuvastatin on atherosclerosis in elderly OSAHS patients

目的探讨松龄血脉康对老年睡眠呼吸暂停综合征(sleep apnea syndrome,SAHS)患者动脉硬化的影响。方法选取在笔者所在医院住院老年SAHS患者136例,且颈动脉内膜中层厚度(IMT)>1.0 mm。随机分为对照组及治疗组。回顾性分析两组患者年龄、体质指数(BMI)、吸烟史、血脂、高血压等动脉硬化危险因素,两组均应用他汀类降脂药物治疗,治疗组另加用松龄血脉康口服。治疗前后两组患者行血清炎性指标超敏C反应蛋白(Hsc RP)及血小板-白细胞聚集体(PLA)的检测,并应用仪器测量肱踝脉搏波传导速度(ba PWV)作为反映外周动脉硬化的评价指标。结果两组患者治疗前后比较,血清Hsc RP及ba PWV指标均降低,PLA百分率增高。两组治疗前后比较均有显著性差异(P<0.05),治疗组差异更显著(P<0.01);两组治疗后比较,治疗组与对照组比较有显著性差异(P<0.05)。结论松龄血脉康联合瑞舒伐他汀可改善睡眠呼吸暂停综合征患者动脉硬化的指标,对老年患者安全有效。

Objective To evauate the effect of Songling Xuemaikang on arteriosclerosis in elderly OSAHS patients. Methods The 136 patients with SAHS were enrolled in this study and randomly divided into treatment group and control group;further more,pationt＇s carotid artery intima-media thickness（IMT） were higher than 1mm. The clinical data about all SAHS patients were analyzed in their age,BMI,smoking-time,hyperlipidemia and hypertension,and so on risk factor. They were given respectively Songling Xuemaikang plus rosuvastatinl and rosuvastatin individually. HscRP,baPWV and PMA were determined before treatment and 12 weeks after treatment. Results The HsCRP,baPwv and PMA were significantly lower after treatment with Songling Xuemaikang （P〈0.05）. There were also a significant difference between two groups after treatment in HscRP, baPWV and PMA （P〈0.05）. Conclusion Songling Xuemaikang is a kind of reliable and safe drug in anti-atherosclerosis with elderly SAHS.